Risk factors

Opus Genetics (IRD) risk factors

Item 1A of every Opus Genetics, Inc. 10-K on file, and what changed from one year to the next.

Open IRD in Gloomberb →
  • FY2025 10-K risk factors

    74 risks, 7 new, 12 dropped, 17 reworded since the prior year. Opus Genetics faces severe share capital constraints with 69.9 million shares issued out of 125 million authorized. The company relies heavily on University of Pennsylvania and University of Florida patent licenses for its gene therapy pipeline. Regulatory oversight risks and Nasdaq minimum bid price compliance dominate the new operational disclosures.

    Filed Mar 12, 2026
  • FY2024 10-K risk factors

    79 risks. Opus Genetics faces integration risks following the Opus Acquisition, relying heavily on its gene therapy pipeline and partner Viatris.

    Filed Mar 31, 2025